Table 2.
Treatment Efficacy (n=94)
| End Point | No RT(n=28) | Early RT(n=31) | Late RT (n=35) |
|---|---|---|---|
| Overall survival | |||
| Median OS (95% CI), month | 16.0 (12.1–19.9) | 25.0 (18.5–31.5) | 29.0 (24.2–33.8) |
| OS rate, % (95% CI) | |||
| 1 year | 75.0 (60.6–92.9) | 77.4 (64.0–93.6) | 85.7 (74.9–98.1) |
| 2 years | 32.1 (18.8–55.1) | 54.8 (39.8–75.5) | 71.4 (57.9–88.1) |
| 3 years | 0.0 (-) | 12.9 (5.2–32.2) | 31.4 (19.3–51.3) |
| Progression-free survival | |||
| Median PFS (95% CI), month | 6.0 (3.8–8.2) | 10.0 (7.3–12.7) | 11.0 (5.2–16.8) |
| PFS rate, % (95% CI) | |||
| 6 months | 53.6 (37.9–75.6) | 71.0 (56.7–88.9) | 88.6 (78.6–99.8) |
| 12 months | 14.3 (5.8–35.4) | 38.7 (24.9–60.3) | 48.6 (34.5–68.3) |
| 24 months | 3.6 (0.5–24.5) | 19.4 (9.4–39.7) | 22.9 (12.4–42.0) |
| Treatment response (%) | |||
| Complete response | 1 (3.6) | 3 (9.7) | 3 (8.6) |
| Partial response | 16 (57.1) | 23 (74.2) | 29 (82.9) |
| Stable disease | 6 (21.4) | 4 (12.9) | 3 (8.6) |
| Progressive disease | 5 (17.9) | 1 (3.2) | 0 (0.0) |
| Overall response | 17 (60.7) | 26 (83.9) | 32 (91.4) |
| Disease control | 23 (82.1) | 30 (96.8) | 35 (100.0) |
Abbreviations: RT, radiotherapy; OS, overall survival; PFS, progression-free survival; CI, confidence interval.